TABLE I.
Characteristics of the Population-based Prostate Cancer (PCa) Patient Cohort According to Outcomes
| Characteristic | No Recurrence (n = 278; 72.6%) | Recurrencea (n = 105; 27.4%) | Lethal PCab (n = 27; 7.1%) | |||
|---|---|---|---|---|---|---|
| n | % | n | % | n | % | |
| Mean age at diagnosis (±sd) | 58 (6.93) | 59 (6.96) | 58 (6.69) | |||
| Mean expression level of 30 cell cycle-regulated genes (±sd) | 8.82 (0.33) | 8.94 (0.38) | 9.13 (0.46) | |||
| Median duration of follow-up, yrs. | 12.4 | 12.2 | 12.5 | |||
| PSA at diagnosis (ng/mL): | ||||||
| 0 – 3.9 | 47 | (16.9) | 13 | (12.4) | 2 | (7.4) |
| 4 – 9.9 | 174 | (62.6) | 41 | (39.0) | 7 | (25.9) |
| 10 – 19.9 | 30 | (10.8) | 26 | (24.8) | 6 | (22.2) |
| 20+ | 11 | (4.0) | 16 | (15.2) | 8 | (29.6) |
| Missing | 16 | (5.8) | 9 | (8.6) | 4 | (14.8) |
| Pathological stage | ||||||
| Localized (T2) | 213 | (76.6) | 44 | (41.9) | 13 | (48.1) |
| Regional (T3) | 65 | (23.4) | 61 | (58.1) | 14 | (51.9) |
| Gleason score | ||||||
| <=6 | 157 | (56.5) | 24 | (22.9) | 5 | (18.5) |
| 7(3+4) | 93 | (33.5) | 49 | (46.7) | 11 | (40.7) |
| 7(4+3) | 15 | (5.4) | 14 | (13.3) | 5 | (18.5) |
| 8–10 | 13 | (4.7) | 18 | (17.1) | 6 | (22.2) |
| TMPRSS2-ERG fusion statusc | ||||||
| Negative | 106 | (40.9) | 42 | (44.2) | 15 | (60.0) |
| Positive | 153 | (59.1) | 53 | (55.8) | 10 | (40.0) |
| 1st Degree family history of PCa | ||||||
| No | 214 | (77.0) | 85 | (81.0) | 23 | (85.2) |
| Yes | 64 | (23.0) | 20 | (19.0) | 4 | (14.8) |
a
Includes patients with biochemical recurrence, secondary treatment, and metastatic or lethal PCa.
b
Includes patients with metastatic or lethal PCa.
c
Number of patients missing TMPRSS2-ERG fusion status: 19, 10, and 2, respectively in the three groups.